| Literature DB >> 33168587 |
.
Abstract
The NCI Molecular Analysis for Therapy Choice trial has demonstrated the feasibility of sequencing tumor DNA and matching patients to targeted therapies according to their cancer's mutation profile. However, response rates of those assigned to a therapy were generally low. ©2021 American Association for Cancer Research.Entities:
Mesh：
Year: 2020 PMID： 33168587 DOI： 10.1158/2159-8290.CD-NB2020-100
Source DB: PubMed Journal: Cancer Discov ISSN： 2159-8274 Impact factor: 39.397